Drug Profile
Valziflocept - Takeda
Alternative Names: BAX 1810; FcγRIIb; Human soluble Fc-gamma receptor IIb - Takeda; OHB-101; SHP 652; SM-101; TAK-752Latest Information Update: 04 Aug 2022
Price :
$50
*
At a glance
- Originator SuppreMol
- Developer Baxalta; Oak Hill Bio; Takeda
- Class Immunoglobulin Fc fragments; Recombinant proteins
- Mechanism of Action Fc gamma receptor IIB modulators; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Idiopathic thrombocytopenic purpura; IgA nephropathy
- Discontinued Chronic obstructive pulmonary disease; Systemic lupus erythematosus
Most Recent Events
- 04 Aug 2022 Oak Hill Bio plans a phase IIb trial in Systemic Lupus Erythematosus (Oak Hill Bio pipeline, August 2022)
- 01 Feb 2022 Phase-II development is ongoing for IgA nephropathy and Idiopathic thrombocytopenic purpura (Oak Hill Bio Pipeline, February 2022)
- 01 Feb 2022 Valziflocept licensed to Oak Hill Bio worldwide